Skip to content
Colorectal Cancer Clinical Trials

Boston, Massachusetts

Colorectal cancer clinical trials in Boston, MA

86 colorectal cancer studies are recruiting participants at sites in Boston as of November 16, 2026, according to ClinicalTrials.gov. Colorectal Cancer Clinical Trials can help you understand your options and connect with a study team.

Call (888) 385-9581
  • No cost to ask
  • Taking part is voluntary
  • Studies are independently reviewed

Boston at a glance

  • 86 studies are recruiting at a site in Boston.
  • By phase: Early Phase 1 (2), Phase 1 (28), Phase 1/2 (24), Phase 2 (7), Phase 2/3 (1), Phase 3 (4), Phase 4 (1), No phase (13), Observational (6). Studies of devices and behavioral approaches have no phase.
  • By sponsor: industry (53), university, hospital or other (33).
  • Most recent update to one of these records: November 16, 2026.

Studies recruiting in Boston

Basic details from each study's public record (the 30 most recently updated of 86). Select a study to read the full record on ClinicalTrials.gov, including how to contact its team.

  1. Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    Boehringer Ingelheim
    Study site
    Dana-Farber Cancer Institute
    Registry record
    NCT06324357 · updated
  2. A Study of ERAS-0015 in Patients With Advanced or Metastatic Solid Tumors

    • Phase 1
    • Ages 18 to 99
    • All sexes
    Sponsor
    Erasca, Inc.
    Study sites
    Dana Farber Cancer Institute · Massachusetts General Hospital (MG)
    Registry record
    NCT06983743 · updated
  3. A Phase 1 Dose Escalation and Dose Expansion Trial of KST-6051 in Participants With Advanced Solid Tumors With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Mutation

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    Kestrel Therapeutics, Inc.
    Study site
    Mass General Brigham Cancer Institute at Massachusetts General Hospital
    Registry record
    NCT07458347 · updated
  4. Prostate Cancer Genetic Risk Evaluation and Screening Study

    • Observational
    • Ages 35 and older
    • Male participants
    Sponsor
    Massachusetts General Hospital
    Study site
    Massachusetts General Hospital
    Registry record
    NCT05129605 · updated
  5. A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    Verastem, Inc.
    Study site
    Massachusetts General Hospital
    Registry record
    NCT07020221 · updated
  6. Phase III Study of Ivonescimab or Bevacizumab Combined With FOLFOX in Patients With Metastatic Colorectal Cancer

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Summit Therapeutics
    Registry record
    NCT07228832 · updated
  7. Five or Ten Year Colonoscopy for 1-2 Non-Advanced Adenomatous Polyps

    • No phase
    • Ages 45 to 70
    • All sexes
    Sponsor
    NRG Oncology
    Study site
    Massachusetts General Hospital Cancer Center
    Registry record
    NCT05080673 · updated
  8. Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease

    • Phase 2/3
    • Ages 18 and older
    • All sexes
    Sponsor
    NRG Oncology
    Study site
    Tufts Medical Center
    Registry record
    NCT05174169 · updated
  9. A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)

    • Phase 2
    • Ages 18 and older
    • All sexes
    Sponsor
    Bayer
    Study site
    Dana-Farber Cancer Institute - Oncology Department
    Registry record
    NCT06760819 · updated
  10. Distance-Based Exercise to Preserve Function and Prevent Disability

    • No phase
    • Ages 18 and older
    • All sexes
    Sponsor
    Alliance for Clinical Trials in Oncology
    Study site
    Dana-Farber Cancer Institute
    Registry record
    NCT07059884 · updated
  11. A Study of LY4257496 in Participants With Cancer (OMNIRAY)

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    Eli Lilly and Company
    Study site
    Dana-Farber Cancer Institute
    Registry record
    NCT07114601 · updated
  12. A Study of LY4337713 in Participants With FAP-Positive Solid Tumors

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    Eli Lilly and Company
    Study site
    Massachusetts General Hospital
    Registry record
    NCT07213791 · updated
  13. Testing the Addition of Total Ablative Therapy to Usual Systemic Therapy Treatment for Limited Metastatic Colorectal Cancer, ERASur Trial

    • Phase 2
    • Ages 18 and older
    • All sexes
    Sponsor
    Alliance for Clinical Trials in Oncology
    Study site
    Boston Medical Center
    Registry record
    NCT05673148 · updated
  14. A Study to Investigate the Safety and Efficacy of KQB365 as Monotherapy and in Combination in Participants With Advanced Solid Malignancies

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    Kumquat Biosciences Inc.
    Study site
    Dana Farber Cancer Institute
    Registry record
    NCT06720987 · updated
  15. A Study to Investigate the Safety and Efficacy of KQB368 as Monotherapy in Participants With Advanced Solid Malignancies

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    Kumquat Biosciences Inc.
    Study site
    Massachusetts General Hospital
    Registry record
    NCT07542704 · updated
  16. A Phase 1 Study of IM-1617 in Participants With Advanced Cancer

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    Immunome, Inc.
    Study site
    Massachusetts General Hospital
    Registry record
    NCT07578571 · updated
  17. A First-in-human Study of RLY-8161 in Advanced NRAS-Mutant Solid Tumors

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    Relay Therapeutics, Inc.
    Study sites
    Dana Farber Cancer Institute · Massachusetts General Hospital
    Registry record
    NCT07584226 · updated
  18. RECTIFY-1: Neoadjuvant Botensilimab + Balstilimab in MSS/pMMR Early Rectal Cancer

    • Phase 2
    • Ages 18 and older
    • All sexes
    Sponsor
    Dana-Farber Cancer Institute
    Study sites
    Brigham and Women's Hospital · Dana-Farber Cancer Institute
    Registry record
    NCT07735624 · updated
  19. A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    Genmab
    Study site
    Massachusetts General Hospital - Dana Farber
    Registry record
    NCT03526835 · updated
  20. First-in-human Study of 7MW4911 in GI Cancer

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    Mabwell (Shanghai) Bioscience Co., Ltd.
    Study site
    Massachusetts General Hospital
    Registry record
    NCT07216560 · updated
  21. LYL273 for Patients With Relapsed or Refractory mCRC

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    Lyell Immunopharma, Inc.
    Study site
    Dana-Farber Cancer Institute
    Registry record
    NCT05319314 · updated
  22. A Study to Evaluate the Adverse Events, and Efficacy of Intravenous (IV) of Telisotuzumab Adizutecan in Combination With IV Oxaliplatin, Fluorouracil, Folinic Acid/Leucovorin, Bevacizumab, Panitumumab in Adult Participants With Metastatic Colorectal Cancer

    • Phase 2
    • Ages 18 and older
    • All sexes
    Sponsor
    AbbVie
    Study site
    Dana-Farber Cancer Institute /ID# 270624
    Registry record
    NCT06820463 · updated
  23. A Study to Learn About Study Medicine ALTA3263 in Adults With Advanced Solid Tumors With KRAS Mutations

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    Alterome Therapeutics, Inc.
    Registry record
    NCT06835569 · updated
  24. The Cancer of the Pancreas Screening-5 CAPS5)Study

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Johns Hopkins University
    Study site
    Dana Farber Cancer Center, Harvard University
    Registry record
    NCT02000089 · updated
  25. A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    Artios Pharma Ltd
    Study site
    Dana Farber Cancer Institute
    Registry record
    NCT04657068 · updated
  26. Study of Denikitug (GS-1811) Given Alone or With Nivolumab or With Chemotherapy in Adults With Advanced Colorectal Cancer

    • Phase 2
    • Ages 18 and older
    • All sexes
    Sponsor
    Gilead Sciences
    Study site
    Beth Israel Deaconess Medical Center
    Registry record
    NCT07527858 · updated
  27. Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    ModeX Therapeutics, An OPKO Health Company
    Study site
    Massachusetts General Hospital
    Registry record
    NCT06239194 · updated
  28. KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    Kura Oncology, Inc.
    Study site
    Dana-Farber Cancer Institute
    Registry record
    NCT06026410 · updated
  29. Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    Institut de Recherches Internationales Servier
    Study site
    Dana-Farber Cancer Institute
    Registry record
    NCT05786924 · updated
  30. An Informational and Supportive Care Intervention for Patients With Locally Advanced Rectal Cancer

    • No phase
    • Ages 18 and older
    • All sexes
    Sponsor
    Massachusetts General Hospital
    Study sites
    Dana-Farber Cancer Institute · Massachusetts General Hospital
    Registry record
    NCT05914766 · updated

Source: ClinicalTrials.gov. Data processed . See every colorectal cancer study recruiting in Boston, MA on ClinicalTrials.gov.

Ask about studies near Boston

Tell us what you are looking for and a coordinator will contact you to talk through your options. Asking does not commit you to anything.

How should we reach you?
Add a message or the best time to reach you (optional)

Please do not include detailed medical information.

Before you contact a study

About these listings

These listings come from ClinicalTrials.gov, the study registry run by the U.S. National Library of Medicine. The data were processed on November 16, 2026. We show part of each public record (its title, phase, sponsor, basic eligibility and sites in this area) exactly as registered, and we group studies by place. Nothing in a record is reworded.

Colorectal Cancer Clinical Trials does not run these studies and is not affiliated with their sponsors. A listing is not a recommendation, and only a study's own team can tell you whether you may be eligible. Follow the link on any study to read its full record and contact that team directly, or ask us and a coordinator will help you understand your options. How we source and check what we publish.

Sources and further reading

Ask about a study

A coordinator will contact you. Asking does not commit you to anything.

Call (888) 385-9581

or send a short form

How should we reach you?

Call